Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23703855 | 0.93 | KDM4E (0.47) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL22206936 | 0.87 | KDM4E (0.61) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL25155768 | 0.86 | KDM4E (0.51) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL21274815 | 0.85 | KDM4E (0.55) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL29752804 | 0.85 | KDM4E (0.55) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL19993672 | 0.85 | MAPT (0.42) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL17185448 | 0.85 | POLB (0.48) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL1263693 | 0.84 | LCK (0.50) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL20772341 | 0.83 | NR1I2 (0.40) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL365903 | 0.83 | MAPT (0.41) | KDM4EPOLBHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| CN-107207473-B | Compounds having muscarinic receptor antagonist and β 2 adrenergic receptor agonist activity | 奇斯药制品公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-3484879-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2019-05-22 | — | — | EP | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| EP-3256464-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| WO-2016128456-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | WO | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161014-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | KDM4E 4716/4885POLB 1610/4885HSD17B10 2092/4885 |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | KDM4E 4511/4885POLB 2018/4885HSD17B10 2117/4885 |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | KDM4E 4511/4885POLB 2018/4885HSD17B10 2117/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | KDM4E 4716/4885POLB 1610/4885HSD17B10 2092/4885 |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | KDM4E 4511/4885POLB 2018/4885HSD17B10 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.